Small-Molecule JAK Inhibitor for Local GI Action With Low Systemic Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors exhibit systemic toxicity and undesirable side effects due to their absorption and distribution throughout the gastrointestinal tract, limiting their use in treating gastrointestinal tract diseases like familial adenomatous polyposis (FAP) and colorectal cancer (CRC).
Innovation Solution
Development of a JAK inhibitor, represented by compound of Formula I, with low systemic toxicity, allowing for pan-JAK inhibition with local gastrointestinal effects and minimal systemic impact, administered orally to treat or prevent gastrointestinal tract diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are administered to treat gastrointestinal tract diseases, then therapeutic effect is achieved, but systemic toxicity and undesirable side effects occur
Solution Approach 1:
The patent applies local quality by designing a JAK inhibitor compound that selectively concentrates in the gastrointestinal tract tissue rather than distributing systemically. The compound achieves high local concentration at the target site (gastrointestinal tract) while maintaining low systemic exposure, thereby providing therapeutic effect locally without causing systemic toxicity. This is accomplished through specific molecular structure design that enables selective accumulation in GI tract tissues.
2Reliability
If JAK inhibitors are used to inhibit the JAK/STAT signaling pathway, then polyp burden is reduced and cancer onset is prevented, but the compound is absorbed and distributed throughout the gastrointestinal tract causing systemic effects
Solution Approach 1:
The patent applies segmentation by dividing the drug distribution pattern into two distinct compartments: high concentration in the gastrointestinal tract (target site) and low concentration in the rest of the body (systemic circulation). This segmented distribution pattern allows the compound to effectively inhibit the JAK/STAT signaling pathway in the GI tract for disease prevention while minimizing systemic side effects. The molecular structure is designed to achieve this spatial segmentation of drug concentration.
3Adaptability or versatility
If systemic JAK inhibition is achieved, then comprehensive disease treatment is possible, but toxicity limits the dosing and therapeutic window
Solution Approach 1:
The patent resolves the dosing limit issue by applying local quality - the compound achieves high local concentration in the gastrointestinal tract at low systemic doses. This enables effective JAK inhibition in the GI tract for comprehensive disease treatment (polyp reduction, cancer prevention) without reaching the systemic toxicity threshold that would limit dosing. The therapeutic window is expanded because the effective local dose is decoupled from the systemic exposure level.
Data Source
AI summary
Disclosed herein are JAK inhibitors that have low systemic toxicity. In some aspects, the disclosure includes methods for treating disease states, disorders, and conditions mediated by JAK, such as stomacho-intestinal system cancers, including colorectal cancers and familial adenomatous polyposis.